Skip to content

Study · Observational study · n = 119 · 2011

6 results

Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.

Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry20 Nov 2010Cited by 6 (Europe PMC)

PMID21095149 (opens in a new tab)DOI10.1016/j.jocd.2010.09.001 (opens in a new tab)PepBankPUB-21095149
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyMechanism

    In PTH-treated osteoporotic women, short-term bone turnover marker changes correlated with one another (r=0.57-0.87, p<0.001).

    In plain wordsIn PTH-treated women with osteoporosis, bone turnover marker changes correlated strongly with one another.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBone turnover marker correlations
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Correlation between short-term changes in bone turnover markers
    0.57 to 0.87 r
    changes in PINP, BAP and CTX; women randomized to PTH(1-84)

    Source sentences

    Summary
    Short-term changes in the markers of bone turnover were highly correlated with one another (r=0.57-0.87, p<0.001).
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
  2. 02HumanObservational studyMechanism

    In PTH-treated osteoporotic women, serum calcium changes correlated modestly with formation marker changes (r=0.22-0.30, p≤0.02).

    In plain wordsIn PTH-treated women, calcium changes correlated modestly with bone formation marker changes.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSerum calcium and formation marker correlation
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Correlation of change in serum calcium with changes in markers of formation
    0.22 to 0.3 r
    women randomized to PTH(1-84)

    Source sentences

    Summary
    In contrast, change in serum calcium correlated only modestly with changes in markers of formation (r=0.22-0.30, p≤0.02)
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
  3. 03HumanObservational studyMechanism

    In PTH-treated osteoporotic women, serum calcium and CTX changes showed a positive, nonsignificant correlation (r=0.13, p=0.18).

    In plain wordsIn PTH-treated women, calcium changes did not correlate significantly with CTX changes.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseSerum calcium and CTX correlation
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Correlation of change in serum calcium with change in CTX
    0.13 r
    women randomized to PTH(1-84); not significant (p=0.18)

    Source sentences

    Summary
    In contrast, change in serum calcium correlated only modestly with changes in markers of formation (r=0.22-0.30, p≤0.02) and did not correlate significantly with change in CTX (r=0.13, p=0.18).
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
  4. 04HumanObservational studyMechanism

    In PTH-treated women, 3-mo BAP increases were greater with hypercalcemia than without it (78% versus 42%, p=0.04).

    In plain wordsIn PTH-treated women, BAP increased more with hypercalcemia than without hypercalcemia.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBAP change by hypercalcemia status
    Study

    n = 119

    Comparator
    Women without hypercalcemia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    3-month BAP increase
    78%
    participants who experienced hypercalcemia
    3-month BAP increase
    42%
    participants who did not experience hypercalcemia

    Source sentences

    Summary
    Participants who experienced hypercalcemia experienced greater 3-mo changes in BAP than those who did not (78% vs. 42% increase in BAP, p=0.04), with similar trends for PINP and CTX.
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
  5. 05HumanObservational studyMechanism

    In PTH-treated women, PINP showed a trend toward greater increases with hypercalcemia than without hypercalcemia.

    In plain wordsIn PTH-treated women, PINP tended to increase more with hypercalcemia than without it.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreasePINP change by hypercalcemia status
    Study

    n = 119

    Comparator
    Women without hypercalcemia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who experienced hypercalcemia experienced greater 3-mo changes in BAP than those who did not (78% vs. 42% increase in BAP, p=0.04), with similar trends for PINP and CTX.
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.
  6. 06HumanObservational studyMechanism

    In PTH-treated women, CTX showed a trend toward greater increases with hypercalcemia than without hypercalcemia.

    In plain wordsIn PTH-treated women, CTX tended to increase more with hypercalcemia than without it.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseCTX change by hypercalcemia status
    Study

    n = 119

    Comparator
    Women without hypercalcemia
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who experienced hypercalcemia experienced greater 3-mo changes in BAP than those who did not (78% vs. 42% increase in BAP, p=0.04), with similar trends for PINP and CTX.
    1 context sentence
    Summary · context
    Baseline and follow-up procollagen type I N propeptide (PINP), bone-specific alkaline phosphatase (BAP), C-terminal telopeptide (CTX), and serum and urinary calcium levels were analyzed post hoc from the 119 postmenopausal women with osteoporosis randomized to PTH(1-84) in the Parathyroid Hormone and Alendronate trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.